As an indicator reflecting the overall metabolic level of the tumor, MTV is suitable for predicting the mutation status of EGFR. In addition, studies have shown that patients with lower MTV have a better prognosis (34–36), while others have reported a significant association between patient prognosis and EGFR mutation status, thus supporting the results of our study. Here, EGFR is linked to neoplasm.